Table 4. Patients’ characteristics.
Variables | n | % |
---|---|---|
Sex | ||
Male | 40 | 71.4 |
Female | 16 | 28.6 |
Age (years) | ||
Median | 69 | |
Range | 21–80 | |
ECOG PS | ||
0 | 21 | 37.5 |
1 | 35 | 62.5 |
Hepatitis | ||
None | 6 | 10.7 |
HBV | 38 | 67.9 |
HCV | 5 | 8.9 |
Alcoholic | 7 | 12.5 |
Liver cirrhosis | ||
No | 16 | 28.6 |
Yes | 40 | 71.4 |
PVTT | ||
No | 25 | 44.6 |
Yes | 31 | 55.4 |
AFP (IU/mL) | ||
< 400 | 40 | 71.4 |
≥ 400 | 16 | 28.6 |
CP class before radiotherapy | ||
A | 47 | 83.9 |
B | 9 | 16.1 |
AJCC stage | ||
II | 8 | 14.3 |
III | 43 | 76.8 |
IVA | 5 | 8.9 |
Previous treatment | ||
None | 6 | 12.5 |
TACE | 49 | 87.5 |
RFA | 7 | 12.5 |
PEI | 4 | 7.1 |
Chemotherapy | 12 | 21.4 |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; HBV, hepatitis B virus; HCV, hepatitis C virus; PVTT, portal vein tumor thrombosis; AFP, alpha-fetoprotein; CP class, Child-Pugh class; AJCC, American Joint Committee on Cancer; TACE, transarterial chemoembolization; RFA, radiofrequency ablation; PEI, percutaneous ethanol injection.